Who
Noah Berkowitz
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Iovance Biotherapeutics; Chief Medical Officer, Arvinas; President & CEO, Synvista Therapeutics.
In numbers
- Trades disclosed
- 159
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $573K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 8 Feb 2007
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 30 Sep 2026filed 2 Oct 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 30 Sep 2026filed 2 Oct 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $110K11,108 at $9.94 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $110K11,108 at $9.94 | filing |
| 18 Mar 2026filed 19 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $71K6,435 at $11.10 | filing |
| 18 Mar 2026filed 19 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $71K6,435 at $11.10 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $68K5,685 at $11.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $68K5,685 at $11.89 | filing |
| 9 May 2025filed 13 May 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —59,600 at $0.00 | filing |
| 18 Mar 2025filed 19 Mar 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $74K8,658 at $8.59 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,330 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —55,229 at $0.00 | filing |
| 18 Mar 2024filed 21 Mar 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,879 at $0.00 | filing |
| 18 Mar 2024filed 21 Mar 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —63,452 at $0.00 | filing |
News
Iovance Biotherapeutics Names Noah Berkowitz CMOfinanzen.ch · 1 Oct 2026Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officermanilatimes.net · 1 Oct 2026Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officerfinanznachrichten.de · 1 Oct 2026Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026
3 headlines in the last 90 days name Noah Berkowitz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.